000411 Zhejiang Int'l Group
- 10.71
- +0.01+0.09%
Zhejiang Int'l Group News
Intel Group (000411.SZ): Net profit of 107 million yuan in the first quarter increased 56.48% year-on-year
On April 26, Ge Longhui Group (000411.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 8.598 billion yuan, up 8.81% year on year; net profit attributable to shareholders of listed companies was 107 million yuan, up 56.48% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 103 million yuan, an increase of 57.45% year on year; basic earnings per share were 0.2067 yuan.
Intel Group (000411.SZ): As of April 19, 2024, the number of shareholders of the company was 28,202
Gelonghui, April 24 | Intel Group (000411.SZ) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 28,674. As of April 19, 2024, the number of shareholders of the company was 28,202.
Intel Group (000411.SZ): 2023 net profit of 489 million yuan, plans to distribute 10 to 3045 yuan
On April 19, Ge Longhui Group (000411.SZ) announced its 2023 annual report. Operating revenue for the reporting period was 32,052 billion yuan, up 4.68% year on year; net profit attributable to shareholders of listed companies was 489 million yuan, up 130.09% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 405 million yuan, up 102.17% year on year; basic earnings per share were 1.09 yuan. The company plans to distribute a total cash dividend of 159 million yuan to all shareholders based on the total share capital on the share registration date when the 2023 equity distribution plan was implemented (including
Intel Group (000411.SZ): As of March 29, 2024, the number of shareholders of the company was 28,705
Gelonghui, April 9 | Intel Group (000411.SZ) said on the investor interactive platform that as of March 29, 2024, the number of shareholders of the company was 28,705.
Intel Group (000411.SZ): Subsidiary Inter Logistics has not carried out drone delivery business
Gelonghui, April 9: An investor asked Intel Group (000411.SZ) on the investor interactive platform, “Does your subsidiary Inter Logistics have a drone delivery business and what proportion of drones are used?” The company replied that the company's subsidiary Intex Logistics has not yet carried out drone delivery business.
Intel Group (000411.SZ): Normal business dealings with companies such as Eli Lilly and Novo Nordisk
GLONGHUI March 13 | Intel Group (000411.SZ) said on the investor interactive platform that the company is a pharmaceutical distribution company, mainly engaged in the wholesale and retail business of pharmaceuticals and medical devices, and has normal business dealings with companies such as Eli Lilly and Novo Nordisk.
Intel Group (000411.SZ): As of March 8, 2024, the number of shareholders of the company was 27,588
Gelonghui March 13 | Intel Group (000411.SZ) said on the investor interactive platform that as of February 29, 2024, the number of shareholders of the company was 27,145. As of March 8, 2024, the number of shareholders of the company was 27,588.
The pharmaceutical business sector fluctuated and picked up, and Intel Group went up and down
Gelonghui, March 8 | The A-share pharmaceutical business sector fluctuated and rose. Inter Group went up and down, Pharmaceuticals Ebuy rose more than 4%, and Liu Pharmaceutical Group, First Pharmaceutical, Yifeng Pharmacy, Chinese Health, etc. followed suit.
Intel Group (000411.SZ): As of January 31, 2024, the number of shareholders of the company was 27,853
Gelonghui, Feb. 7 | Intel Group (000411.SZ) said on the investor interactive platform that as of January 31, 2024, the number of shareholders of the company was 27,853.
Intel Group (000411.SZ): As of January 10, 2024, the number of shareholders of the company was 28,236
Gelonghui January 24 | Intel Group (000411.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 28,236.
Express News | Intel Group: Net profit in 2023 is expected to increase 18.58% — 37.25% over the same period last year after the restructuring
Intel Group (000411.SZ): The company is mainly engaged in the wholesale and retail business of pharmaceuticals and medical devices
Gelonghui, January 4 | Intel Group (000411.SZ) said on the investor interactive platform that the company is a pharmaceutical distribution enterprise, mainly engaged in the wholesale and retail business of pharmaceuticals and medical devices. The company strictly complies with relevant laws and regulations, operates in compliance, and sells all kinds of pharmaceuticals normally.
Intel Group (000411.SZ): The cross-border e-commerce business is dominated by Inter International Pharmaceuticals and is currently in the initial development stage
Gelonghui, December 27丨An investor asked Intel Group (000411.SZ) on the investor interactive platform, “Please ask if the development status of your cross-border e-commerce business will be beneficial to the company's development.” The company replied that the company's cross-border e-commerce business is mainly based on Intex International Pharmaceuticals. Currently, it is in its infancy and sales are not large.
Intel Group (000411.SZ): Currently developing a small amount of medical and aesthetic business, accounting for a very small proportion of the company's business
Gelonghui, December 27丨An investor asked Inter Group (000411.SZ) on the investor interactive platform, “Does Zhejiang Entel Biological Products Marketing Co., Ltd. involve the medical and aesthetic industry?” The company replied that the company is currently carrying out a small amount of medical and aesthetic business, accounting for a very small proportion of the company's business.
The A-share pharmaceutical commercial sector boosted, and Intel Group rose more than 5%
Gelonghui, December 18 | Intel Group rose more than 5%, and Zhejiang Zhenyuan, Kyushu Express, Guoke Hengtai, Jiashitang, Baiyang Pharmaceutical, etc. followed suit.
Intel Group (000411.SZ): Carrying out relevant vaccine cold chain distribution services in an orderly manner
On December 8, Gelonghui Group (000411.SZ) stated on the investor interactive platform that the company is carrying out relevant vaccine cold chain distribution services in an orderly manner, but it accounts for a very small proportion of the company's business.
Intel Group (000411.SZ): No pharmaceutical plants
On December 8, Gelonghui Group (000411.SZ) stated on the investor interactive platform that Inter Pharmaceutical is a pharmaceutical distribution company, mainly engaged in the wholesale and retail business of pharmaceuticals and medical devices, has no pharmaceutical factories, and has a stake in Zhejiang Huarun Inter Traditional Chinese Medicine Co., Ltd. For details, please refer to the company's 2023 semi-annual report disclosed on Juchao Information Network.
Intel Group (000411.SZ): As of November 30, 2023, the number of company shareholders is 27998
On December 8, Gelonghui Group (000411.SZ) stated on the investor interactive platform that the Inter Pharmaceutical Valley online trading platform is operating normally. As of November 30, 2023, the number of shareholders in the company was 27,998.
Intel Group (000411.SZ): Normal development of GLP-1 related product business
On November 7, Gelonghui Group (000411.SZ) stated on the investor interactive platform that the company is carrying out GLP-1 related product business normally and continues to connect and cooperate with companies such as Lilly and Novo Nordisk.
Intel Group (000411.SZ): Net profit of 366 million yuan for the first three quarters increased 128.02% year-on-year
On October 27, Gelonghui Group (000411.SZ) announced its third quarter report. Operating income was 23.918 billion yuan, up 7.19% year on year, net profit was 366 million yuan, up 128.02% year on year, net profit was 128.02% year on year, net profit was 273 million yuan, net profit was 273 million yuan, up 81.14% year on year, and basic earnings per share were 0.8014 yuan.
Analysis
Price Target
No Data
